50,200 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Bayesian Capital Management LP

Bayesian Capital Management LP purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 50,200 shares of the biopharmaceutical company’s stock, valued at approximately $591,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Van ECK Associates Corp raised its holdings in shares of Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 873 shares during the period. Calton & Associates Inc. acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $142,000. EntryPoint Capital LLC grew its position in shares of Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 9,729 shares in the last quarter. Old Well Partners LLC acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $180,000. Finally, Mesirow Financial Investment Management Inc. acquired a new position in shares of Amicus Therapeutics during the 1st quarter worth approximately $225,000.

Amicus Therapeutics Stock Down 0.3 %

Shares of NASDAQ FOLD traded down $0.03 during trading hours on Tuesday, hitting $10.08. 2,300,246 shares of the stock were exchanged, compared to its average volume of 2,817,013. The company has a debt-to-equity ratio of 2.97, a quick ratio of 2.61 and a current ratio of 3.03. The company’s fifty day simple moving average is $10.09 and its two-hundred day simple moving average is $11.21. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The business had revenue of $110.40 million during the quarter, compared to the consensus estimate of $111.19 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. The firm’s revenue was up 27.9% compared to the same quarter last year. Analysts forecast that Amicus Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. UBS Group decreased their target price on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, May 10th. Guggenheim upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, May 14th. Bank of America decreased their target price on shares of Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, Wells Fargo & Company initiated coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target on the stock. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.57.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,928,605.78. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,928,605.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,866,540. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.